-
1
Reduced MAPSE alone should not trigger inotropic therapy; treatment decisions should reflect the patient’s overall hemodynamic and clinical status.
-
2
The study assessed MAPSE feasibility and prognostic value across a heterogeneous ICU population, viewing it as a bedside risk-stratification marker alongside other findings.
-
3
After adjustment for age, SAPS 3, and cardiac index, lower MAPSE remained independently associated with 90-day mortality, whereas LVEF did not.
-
4
MAPSE measurement was substantially more feasible than Simpson biplane LVEF measurement in this critically ill population.
-
5
The authors retained patients with mitral annular calcification and called for studies with prespecified etiologic strata, interaction analyses, and serial echocardiography.
